Citadel Advisors
JBIO

Citadel Advisors’s Jade Biosciences JBIO Stock Holding History

Citadel Advisors’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.7M Buy
929,407
+792,185
+577% +$16.5M ﹤0.01% 2539
2026
Q1 		$1.93M Buy
137,222
+101,167
+281% +$1.46M ﹤0.01% 6137
2025
Q4 		$556K Buy
+36,055
New +$423K ﹤0.01% 8771
2025
Q2 		– Sell
-899
Closed -$79K – 12502
2025
Q1 		$79K Buy
899
+740
+465% +$65K ﹤0.01% 11780
2024
Q4 		$14.7K Buy
+159
New +$13.7K ﹤0.01% 13394
2023
Q3 		– Sell
-8,341
Closed -$5.01M – 14266
2023
Q2 		$5.01M Buy
+8,341
New +$5.33M ﹤0.01% 3645
2023
Q1 		– Sell
-44,626
Closed -$45.8M – 14688
2022
Q4 		$45.8M Sell
44,626
-1,533
-3% -$1.11M 0.01% 1190
2022
Q3 		$26.8M Buy
46,159
+673
+1% +$449K 0.01% 1597
2022
Q2 		$24.9M Sell
45,486
-39
-0.1% -$18.6K 0.01% 1624
2022
Q1 		$29.2M Sell
45,525
-117
-0.3% -$45.4K 0.01% 1579
2021
Q4 		$18.8M Buy
45,642
+76
+0.2% +$38.4K ﹤0.01% 2099
2021
Q3 		$32.4M Sell
45,566
-577
-1% -$323K 0.01% 1503
2021
Q2 		$35.5M Buy
+46,143
New +$36.9M 0.01% 1434

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors's JBIO Position: Q2 2026 in Review

Citadel Advisors increased its Jade Biosciences (JBIO) stake by 577% in Q2 2026, buying an estimated $16.5M and bringing the position to 929,407 shares worth $20.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2539.

Citadel Advisors first reported a position in JBIO in Q2 2021 and has held it in 13 quarters since. The position peaked at $45.8M in Q4 2022. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Citadel Advisors held 929,407 shares of Jade Biosciences worth $20.7M as of Q2 2026.
  • Citadel Advisors bought 792,185 Jade Biosciences shares in Q2 2026, an estimated $16.5M.
  • Jade Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2539 holding.
  • Citadel Advisors first reported a position in Jade Biosciences in Q2 2021 and has held it in 13 quarters since.
  • Citadel Advisors's Jade Biosciences position peaked at $45.8M in Q4 2022.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.